AngioDynamics, Inc. (NASDAQ:ANGO) is scheduled to issue its quarterly earnings data before the market opens on Thursday, March 30th. Analysts expect the company to announce earnings of $0.15 per share for the quarter. AngioDynamics has set its FY17 guidance at $0.65-0.67 EPS.
AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Friday, January 6th. The company reported $0.19 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.03. The business earned $89 million during the quarter. AngioDynamics had a positive return on equity of 4.87% and a negative net margin of 7.91%. The business’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.14 earnings per share. On average, analysts expect AngioDynamics to post $0.67 EPS for the current fiscal year and $0.75 EPS for the next fiscal year.
Shares of AngioDynamics, Inc. (NASDAQ:ANGO) opened at 16.99 on Tuesday. AngioDynamics, Inc. has a 12-month low of $10.71 and a 12-month high of $18.18. The firm’s market capitalization is $620.20 million. The company has a 50-day moving average price of $16.63 and a 200-day moving average price of $16.71.
Several brokerages have commented on ANGO. Zacks Investment Research downgraded shares of AngioDynamics from a “hold” rating to a “sell” rating in a report on Friday, March 10th. Canaccord Genuity reissued a “hold” rating and issued a $17.50 price target on shares of AngioDynamics in a report on Monday, February 27th. Barclays PLC began coverage on shares of AngioDynamics in a report on Wednesday, February 8th. They issued an “equal weight” rating and a $17.00 price target for the company. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $19.00 price target on shares of AngioDynamics in a report on Tuesday, December 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $17.08.
TRADEMARK VIOLATION NOTICE: “AngioDynamics, Inc. (ANGO) Scheduled to Post Quarterly Earnings on Thursday” was originally published by Mideast Time and is the sole property of of Mideast Time. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.mideasttime.com/angiodynamics-inc-ango-scheduled-to-post-quarterly-earnings-on-thursday/1589769.html.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.